Monitoring mutant KRAS in plasma cell-free DNA can predict disease progression in a patient with multiple myeloma: A case report.

MLA

Yamamoto, Masayo, et al. “Monitoring Mutant KRAS in Plasma Cell-Free DNA Can Predict Disease Progression in a Patient with Multiple Myeloma: A Case Report.” Clinica Chimica Acta, vol. 551, Nov. 2023, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.cca.2023.117590.

APA

Yamamoto, M., Shindo, M., Funayama, T., Sumi, C., Saito, T., Toki, Y., Hatayama, M., Ono, Y., Sato, K., Mizukami, Y., & Okumura, T. (2023). Monitoring mutant KRAS in plasma cell-free DNA can predict disease progression in a patient with multiple myeloma: A case report. Clinica Chimica Acta, 551, N.PAG. https://doi.org/10.1016/j.cca.2023.117590

Chicago

Yamamoto, Masayo, Motohiro Shindo, Takuya Funayama, Chihiro Sumi, Takeshi Saito, Yasumichi Toki, Mayumi Hatayama, et al. 2023. “Monitoring Mutant KRAS in Plasma Cell-Free DNA Can Predict Disease Progression in a Patient with Multiple Myeloma: A Case Report.” Clinica Chimica Acta 551 (November): N.PAG. doi:10.1016/j.cca.2023.117590.